Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 19;11:16839. doi: 10.1038/s41598-021-96107-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Experimental design for siCASP2 and siEGFP injection studies. (A) Timeline “post-blast” study. Bilateral siCASP2 or siEGFP control were intravitreally injection 5 h after the initial 2 × 15 psi blast wave, and injections repeated every 7 days until perfusion and tissue collection at 28 dpi. (B) Experimental groups for “post-blast” injection study. (C) Timeline for “pre-blast” study. Bilateral siCASP2 or siEGFP controls were intravitreally injected 48 h before the initial 2 × 15 psi blast exposure and injections repeated every 7 d until perfusion and tissue collection at 14 dpi. (D) Experimental groups for “pre-blast” study. (E) Measured endpoints and eyes analysed.